ClinicalTrials.gg
Not yet recruitingNCT07618845Updated Jun 1, 2026

A Clinical Trial to Assess the Pharmacokinetics, Safety, and Food Effect of AD-230 in Healthy Adults

A Phase 1 interventional study of AD-230 (Fasted) and AD-230 (Fed) in Chronic Liver Disease (CLD), sponsored by Addpharma Inc.. Not yet recruiting at 1 site in South Korea. Open to participants aged 19 Years to 64 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-06-01.

Sponsored by Addpharma Inc. (part of Yuhan Corporation) · Phase 1, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Jul 2026, 4 months ago, but the record still lists the study as not yet recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
24
Allocation
Randomized
Ages
19 Years to 64 Years
Sex
All
01

Study summary

A clinical trial to assess the pharmacokinetics, safety, and food effect of AD-230 in healthy adults

02

Conditions studied

  • Chronic Liver Disease (CLD)
03

In context

Lead sponsor

Addpharma Inc. is the lead sponsor of 58 studies on the registry; 25 are open to participants now.

First submitted after Addpharma Inc. became part of Yuhan Corporation.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
19 Years to 64 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • (BMI) between 18.5 kg/m2 and 29.9 kg/m2 at the time of screening visit
  • Subjects aged 19 years or older and under 65 years at the screening visit

Exclusion criteria

Exclusion Criteria:

  • Participation in another clinical study with an drug within the 6 months from scheduled first administration
  • Other exclusions applied
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
24 participants (estimated)

Study arms

  • Experimental
    Sequence A

    Period 1: Fasted, Period 2: Fed

    Drug: AD-230 (Fasted) · Drug: AD-230 (Fed)

  • Experimental
    Sequence B

    Period 1: Fed, Period 2: Fasted

    Drug: AD-230 (Fasted) · Drug: AD-230 (Fed)

Interventions

  • DrugAD-230 (Fasted)

    AD-230 1Tab., Per Oral, Fasted

  • DrugAD-230 (Fed)

    AD-230 1 Tab., Per Oral, Fed state

06

What researchers measure

Primary outcomes

  1. Area under the plasma concentration-time curve during dosing interval (AUCt)

    Time frame: -24hours to 72hours

  2. Maximum concentration of drug in plasma (Cmax)

    Time frame: -24hours to 72hours

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for May 2026; primary completion for Jul 2026, 2 months later.

How these figures are worked out, and which studies are left out of them.

Registered
May 26, 2026
First posted
Jun 1, 2026
StartEst.
May 2026
Primary completionEst.
Jul 2026
CompletionEst.
Jul 2026
Last update
Jun 1, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 1, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07618845
Lead sponsor
Addpharma Inc.
Responsible party
Sponsor
First posted
Jun 1, 2026
Start date
May 2026 (estimated)
Primary completion
Jul 2026 (estimated)
Completion
Jul 2026 (estimated)
Last update
Jun 1, 2026

Study contacts

Sarah Yoon
Contact
sryoon@addpharma.co.kr
031-891-5576

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion